Amid the topmost stocks in today’s market is Abbott Laboratories (NYSE:ABT). Abbott Laboratories had a market cap of 67530.17, indicating that it has a good hold on the market value of the shares outstanding. The current market cap of Abbott Laboratories exhibits the basic determinant of asset allocation and risk-return parameters for its stocks.
The P/E of Abbott Laboratories is currently valued at 26.95 allowing its investors to analyze the company’s stock valuation and its shares relative to the income of the company that it makes. With the constructive P/E value of Abbott Laboratories, the investors are able to forecast the positive earnings growth of the company.
The forward P/E of Abbott Laboratories is at 18.99 signifying the uses of estimated net earnings over the next 12 months. Investors will be getting a good grip in comparing the current earnings of the company to estimated future earnings.
With its low price-to-sales ratio of 3.29, the company is evidently a better investment since the investors are paying a lower amount for each unit of sales. However, the company sales do not necessarily expose the entire picture, as it might be unprofitable with a low P/S ratio.
The price-to-book ratio of 3.21 for Abbott Laboratories (NYSE:ABT) implies that investors are highly hopeful for the organization to create more value from the given set of assets. The market value of the firm’s assets are considerably higher in contrast to their accounting value. The current P/B amount of Abbott Laboratories best indicates the value approach in differentiating good from the bad. The ratio also provides a clue to how much investors are paying for what would be left if the company went bankrupt immediately.
The target payout ratio for Abbott Laboratories is currently measuring at 31.70%, outlining what size the company’s dividends should be. It also demonstrates a stable dividend policy for Abbott Laboratories connected to the long-run, with viable earnings.
The EPS for Abbott Laboratories is valued at 1.68 with an EPS growth this year at -10.30%. The company’s EPS growth for the following year is valued at 10.58%, indicating an EPS value of -21.10% for the past 5 years, and an EPS value of 10.17% for the coming five years.
Abbott Laboratories’s sales for the past 5 years rolls at -8.00%, exhibiting an EPS growth from quarter-to-quarter at 37.90%. The sales growth of the company is 1.40% at the moment, indicating the average sales volume of the company’s products and services that have typically improved year-to-year.
Company’s existing stock price is at 45.21 with a change in price of -0.13%. As of now, the target price for the company is measuring at 51.32. Abbott Laboratories’s ROA is rolling at 10.70%, following the ROI of 6.20%. Quick and current ratio is valued at 1.5 and 1.8 respectively.